{"pmid":32293753,"title":"The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis.","text":["The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis.","AIMS: Comorbidities are associated with the severity of Coronavirus Disease 2019 (Covid-19). This meta-analysis aimed to explore the risk of severe Covid-19 in patients with pre-existing chronic obstructive pulmonary disease (COPD) and ongoing smoking history. METHODS: A comprehensive systematic literature search was carried out to find studies published from December 2019 to 22nd March 2020 from 5 Database. The language of literature included English and Chinese. The point prevalence of severe Covid-19 in patients with pre-existing COPD and those with ongoing smoking was evaluated with this meta-analysis. RESULTS: Overall 11 case-series, published either in Chinese or English language with a total of 2002 cases were included in the study. The pooled OR of COPD and the development of severe Covid-19 was 4.38 (Fixed effect model, 95% CI: 2.34-8.20), while the OR of ongoing smoking was 1.98 (Fixed effect model, 95% CI: 1.29-3.05). There was no publication bias as examined by the funnel plot and Egger's test (p=NS). The heterogeneity of included studies was moderate for both COPD and ongoing smoking history on the severity of Covid-19. CONCLUSIONS: COPD and ongoing smoking history attribute to the worse progression and outcome of Covid-19. This article is protected by copyright. All rights reserved.","J Med Virol","Zhao, Qianwen","Meng, Meng","Kumar, Rahul","Wu, Yinlian","Huang, Jiaofeng","Lian, Ningfang","Deng, Yunlei","Lin, Su","32293753"],"abstract":["AIMS: Comorbidities are associated with the severity of Coronavirus Disease 2019 (Covid-19). This meta-analysis aimed to explore the risk of severe Covid-19 in patients with pre-existing chronic obstructive pulmonary disease (COPD) and ongoing smoking history. METHODS: A comprehensive systematic literature search was carried out to find studies published from December 2019 to 22nd March 2020 from 5 Database. The language of literature included English and Chinese. The point prevalence of severe Covid-19 in patients with pre-existing COPD and those with ongoing smoking was evaluated with this meta-analysis. RESULTS: Overall 11 case-series, published either in Chinese or English language with a total of 2002 cases were included in the study. The pooled OR of COPD and the development of severe Covid-19 was 4.38 (Fixed effect model, 95% CI: 2.34-8.20), while the OR of ongoing smoking was 1.98 (Fixed effect model, 95% CI: 1.29-3.05). There was no publication bias as examined by the funnel plot and Egger's test (p=NS). The heterogeneity of included studies was moderate for both COPD and ongoing smoking history on the severity of Covid-19. CONCLUSIONS: COPD and ongoing smoking history attribute to the worse progression and outcome of Covid-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhao, Qianwen","Meng, Meng","Kumar, Rahul","Wu, Yinlian","Huang, Jiaofeng","Lian, Ningfang","Deng, Yunlei","Lin, Su"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293753","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25889","keywords":["COPD","Covid-2019","smoking"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266295813603328,"score":8.233237,"similar":[{"pmid":32232218,"pmcid":"PMC7096724","title":"Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","text":["Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively.","Arch Acad Emerg Med","Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali","32232218"],"abstract":["Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively."],"journal":"Arch Acad Emerg Med","authors":["Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232218","week":"202014|Mar 30 - Apr 05","keywords":["COVID-19","Comorbidity","Meta-analysis","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663352135424671744,"score":583.3407},{"pmid":32267833,"title":"Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.","text":["Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.","Currently, the number of patients with coronavirus disease 2019 (COVID-19) has increased rapidly, but relationship between comorbidity and patients with COVID-19 still not clear. The aim was to explore whether the presence of common comorbidities increases COVID-19 patients' risk. A literature search was performed using the electronic platforms (PubMed, Cochrane Library, Embase, and other databases) to obtain relevant research studies published up to March 1, 2020. Relevant data of research endpoints in each study were extracted and merged. All data analysis was performed using Stata12.0 software. A total of 1558 patients with COVID-19 in 6 studies were enrolled in our meta-analysis eventually. Hypertension (OR: 2.29, P<0.001), diabetes (OR: 2.47, P<0.001), chronic obstructive pulmonary disease (COPD) (OR: 5.97, P<0.001), cardiovascular disease (OR: 2.93, P<0.001), and cerebrovascular disease (OR:3.89, P=0.002)were independent risk factors associated with COVID-19 patients. The meta-analysis revealed no correlation between increased risk of COVID-19 and liver disease, malignancy, or renal disease. Hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are major risk factors for patients with COVID-19. Knowledge of these risk factors can be a resource for clinicians in the early appropriate medical management of patients with COVID-19.","Aging (Albany NY)","Wang, Bolin","Li, Ruobao","Lu, Zhong","Huang, Yan","32267833"],"abstract":["Currently, the number of patients with coronavirus disease 2019 (COVID-19) has increased rapidly, but relationship between comorbidity and patients with COVID-19 still not clear. The aim was to explore whether the presence of common comorbidities increases COVID-19 patients' risk. A literature search was performed using the electronic platforms (PubMed, Cochrane Library, Embase, and other databases) to obtain relevant research studies published up to March 1, 2020. Relevant data of research endpoints in each study were extracted and merged. All data analysis was performed using Stata12.0 software. A total of 1558 patients with COVID-19 in 6 studies were enrolled in our meta-analysis eventually. Hypertension (OR: 2.29, P<0.001), diabetes (OR: 2.47, P<0.001), chronic obstructive pulmonary disease (COPD) (OR: 5.97, P<0.001), cardiovascular disease (OR: 2.93, P<0.001), and cerebrovascular disease (OR:3.89, P=0.002)were independent risk factors associated with COVID-19 patients. The meta-analysis revealed no correlation between increased risk of COVID-19 and liver disease, malignancy, or renal disease. Hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are major risk factors for patients with COVID-19. Knowledge of these risk factors can be a resource for clinicians in the early appropriate medical management of patients with COVID-19."],"journal":"Aging (Albany NY)","authors":["Wang, Bolin","Li, Ruobao","Lu, Zhong","Huang, Yan"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267833","week":"202015|Apr 06 - Apr 12","doi":"10.18632/aging.103000","keywords":["COVID-19","comorbidity","meta-analysis","risk"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663609715827933185,"score":436.40625},{"pmid":32173574,"title":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.","text":["Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.","BACKGROUND: An outbreak of Novel Coronavirus (COVID -19) in Wuhan, China, the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of the meta-analysis was to assess the prevalence of comorbidities in the COVID-19 infection patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of sciences until February 25, 2020. Risk ratio (OR) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Eight studies were included in the meta- analysis, including 46248 infected patients. The result showed the most prevalent clinical symptom was fever ( 91 +/- 3, 95% CI 86-97% ), followed by cough (67 +/- 7, 95% CI 59-76%), fatigue ( 51 +/- 0, 95% CI 34-68% ) and dyspnea ( 30 +/- 4, 95% CI 21-40%). The most prevalent comorbidity were hypertension (17 +/- 7, 95% CI 14-22%) and diabetes ( 8 +/- 6, 95% CI 6-11% ), followed by cardiovascular diseases ( 5 +/- 4, 95% CI 4-7% ) and respiratory system disease( 2 +/- 0, 95% CI 1-3% ). Compared with the Non-severe patient, the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 3.42, 95% CI: 1.88-6.22)respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 infection patients and found underlying disease, including hypertension, respiratory system disease and cardiovascular, may be a risk factor for severe patients compared with Non-severe patients.","Int J Infect Dis","Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning","32173574"],"abstract":["BACKGROUND: An outbreak of Novel Coronavirus (COVID -19) in Wuhan, China, the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of the meta-analysis was to assess the prevalence of comorbidities in the COVID-19 infection patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of sciences until February 25, 2020. Risk ratio (OR) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Eight studies were included in the meta- analysis, including 46248 infected patients. The result showed the most prevalent clinical symptom was fever ( 91 +/- 3, 95% CI 86-97% ), followed by cough (67 +/- 7, 95% CI 59-76%), fatigue ( 51 +/- 0, 95% CI 34-68% ) and dyspnea ( 30 +/- 4, 95% CI 21-40%). The most prevalent comorbidity were hypertension (17 +/- 7, 95% CI 14-22%) and diabetes ( 8 +/- 6, 95% CI 6-11% ), followed by cardiovascular diseases ( 5 +/- 4, 95% CI 4-7% ) and respiratory system disease( 2 +/- 0, 95% CI 1-3% ). Compared with the Non-severe patient, the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 3.42, 95% CI: 1.88-6.22)respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 infection patients and found underlying disease, including hypertension, respiratory system disease and cardiovascular, may be a risk factor for severe patients compared with Non-severe patients."],"journal":"Int J Infect Dis","authors":["Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173574","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.ijid.2020.03.017","keywords":["2019-nCoV","COVID-19","Clinical characteristics","Comorbidities","Epidemiologicalm","Meta-analysis"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1663352133914722304,"score":379.97556},{"pmid":32251668,"title":"Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis.","text":["Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis.","BACKGROUND & AIMS: Infection with SARS-CoV-2 causes COVID-19, which has been characterized by fever, respiratory, and gastrointestinal symptoms as well as shedding of virus RNA into feces. We performed a systematic review and meta-analysis of published gastrointestinal symptoms and detection of virus in stool, and also summarized data from a cohort of patients with COVID-19 in Hong Kong. METHODS: We collected data from the cohort of patients with COVID-19 in Hong Kong (n=59; diagnosis from February 2 through Feb 29, 2020), and searched PubMed, Embase, Cochrane and three Chinese databases through March 11, 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, and abdominal pain or discomfort) using a random effects model. RESULTS: Among the 59 patients with COVID-19 in Hong Kong, 15 patients (25.4%) had gastrointestinal symptoms and 9 patients (15.3%) had stool that tested positive for virus RNA. Stool viral RNA was detected in 38.5% and 8.7% among those with and without diarrhea, respectively (P=.02). The median fecal viral load was 5.1 log10cpm in patients with diarrhea vs 3.9 log10cpm in patients without diarrhea (P=.06). In a meta-analysis of 60 studies, comprising 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6% (95% CI, 12.3%-24.5%); 11.8% of patients with non-severe COVID-19 had gastrointestinal symptoms (95% CI, 4.1%-29.1%) and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms (95% CI, 6.9%-36.7%). In the meta-analysis, the pooled prevalence of stool samples that were positive for virus RNA was 48.1% (95% CI, 38.3%-57.9%); of these samples, 70.3% of those collected after loss of virus from respiratory specimens tested positive for the virus (95% CI, 49.6%-85.1%). CONCLUSIONS: In an analysis of data from the Hong Kong cohort of patients with COVID-19 and a meta-analysis of findings from publications, we found that 17.6% of patients with COVID-19 had gastrointestinal symptoms. Virus RNA was detected in stool samples from 48.1% patients-even in stool collected after respiratory samples tested negative. Healthcare workers should therefore exercise caution in collecting fecal samples or performing endoscopic procedures in patients with COVID-19-even during patient recovery.","Gastroenterology","Cheung, Ka Shing","Hung, Ivan Fn","Chan, Pierre Py","Lung, K C","Tso, Eugene","Liu, Raymond","Ng, Y Y","Chu, Man Y","Chung, Tom Wh","Tam, Anthony Raymond","Yip, Cyril Cy","Leung, Kit-Hang","Yim-Fong Fung, Agnes","Zhang, Ricky R","Lin, Yansheng","Cheng, Ho Ming","Zhang, Anna Jx","To, Kelvin Kw","Chan, Kwok-H","Yuen, Kwok-Y","Leung, Wai K","32251668"],"abstract":["BACKGROUND & AIMS: Infection with SARS-CoV-2 causes COVID-19, which has been characterized by fever, respiratory, and gastrointestinal symptoms as well as shedding of virus RNA into feces. We performed a systematic review and meta-analysis of published gastrointestinal symptoms and detection of virus in stool, and also summarized data from a cohort of patients with COVID-19 in Hong Kong. METHODS: We collected data from the cohort of patients with COVID-19 in Hong Kong (n=59; diagnosis from February 2 through Feb 29, 2020), and searched PubMed, Embase, Cochrane and three Chinese databases through March 11, 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, and abdominal pain or discomfort) using a random effects model. RESULTS: Among the 59 patients with COVID-19 in Hong Kong, 15 patients (25.4%) had gastrointestinal symptoms and 9 patients (15.3%) had stool that tested positive for virus RNA. Stool viral RNA was detected in 38.5% and 8.7% among those with and without diarrhea, respectively (P=.02). The median fecal viral load was 5.1 log10cpm in patients with diarrhea vs 3.9 log10cpm in patients without diarrhea (P=.06). In a meta-analysis of 60 studies, comprising 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6% (95% CI, 12.3%-24.5%); 11.8% of patients with non-severe COVID-19 had gastrointestinal symptoms (95% CI, 4.1%-29.1%) and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms (95% CI, 6.9%-36.7%). In the meta-analysis, the pooled prevalence of stool samples that were positive for virus RNA was 48.1% (95% CI, 38.3%-57.9%); of these samples, 70.3% of those collected after loss of virus from respiratory specimens tested positive for the virus (95% CI, 49.6%-85.1%). CONCLUSIONS: In an analysis of data from the Hong Kong cohort of patients with COVID-19 and a meta-analysis of findings from publications, we found that 17.6% of patients with COVID-19 had gastrointestinal symptoms. Virus RNA was detected in stool samples from 48.1% patients-even in stool collected after respiratory samples tested negative. Healthcare workers should therefore exercise caution in collecting fecal samples or performing endoscopic procedures in patients with COVID-19-even during patient recovery."],"journal":"Gastroenterology","authors":["Cheung, Ka Shing","Hung, Ivan Fn","Chan, Pierre Py","Lung, K C","Tso, Eugene","Liu, Raymond","Ng, Y Y","Chu, Man Y","Chung, Tom Wh","Tam, Anthony Raymond","Yip, Cyril Cy","Leung, Kit-Hang","Yim-Fong Fung, Agnes","Zhang, Ricky R","Lin, Yansheng","Cheng, Ho Ming","Zhang, Anna Jx","To, Kelvin Kw","Chan, Kwok-H","Yuen, Kwok-Y","Leung, Wai K"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251668","week":"202015|Apr 06 - Apr 12","doi":"10.1053/j.gastro.2020.03.065","keywords":["PRISMA","SARS","fecal to oral transmission","viral persistence"],"source":"PubMed","locations":["Chinese","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Prevention","Transmission"],"weight":1,"_version_":1663352136293941248,"score":364.82376},{"pmid":32179124,"pmcid":"PMC7102608","title":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.","text":["Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.","INTRODUCTION: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. METHODS: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI). RESULTS: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 95%CI 40.8-74.4%) and dyspnea (45.6%, 95%CI 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). CONCLUSION: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19.","Travel Med Infect Dis","Rodriguez-Morales, Alfonso J","Cardona-Ospina, Jaime A","Gutierrez-Ocampo, Estefania","Villamizar-Pena, Rhuvi","Holguin-Rivera, Yeimer","Escalera-Antezana, Juan Pablo","Alvarado-Arnez, Lucia Elena","Bonilla-Aldana, D Katterine","Franco-Paredes, Carlos","Henao-Martinez, Andres F","Paniz-Mondolfi, Alberto","Lagos-Grisales, Guillermo J","Ramirez-Vallejo, Eduardo","Suarez, Jose A","Zambrano, Lysien I","Villamil-Gomez, Wilmer E","Balbin-Ramon, Graciela J","Rabaan, Ali A","Harapan, Harapan","Dhama, Kuldeep","Nishiura, Hiroshi","Kataoka, Hiromitsu","Ahmad, Tauseef","Sah, Ranjit","32179124"],"abstract":["INTRODUCTION: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. METHODS: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI). RESULTS: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 95%CI 40.8-74.4%) and dyspnea (45.6%, 95%CI 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). CONCLUSION: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19."],"journal":"Travel Med Infect Dis","authors":["Rodriguez-Morales, Alfonso J","Cardona-Ospina, Jaime A","Gutierrez-Ocampo, Estefania","Villamizar-Pena, Rhuvi","Holguin-Rivera, Yeimer","Escalera-Antezana, Juan Pablo","Alvarado-Arnez, Lucia Elena","Bonilla-Aldana, D Katterine","Franco-Paredes, Carlos","Henao-Martinez, Andres F","Paniz-Mondolfi, Alberto","Lagos-Grisales, Guillermo J","Ramirez-Vallejo, Eduardo","Suarez, Jose A","Zambrano, Lysien I","Villamil-Gomez, Wilmer E","Balbin-Ramon, Graciela J","Rabaan, Ali A","Harapan, Harapan","Dhama, Kuldeep","Nishiura, Hiroshi","Kataoka, Hiromitsu","Ahmad, Tauseef","Sah, Ranjit"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32179124","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.tmaid.2020.101623","keywords":["Clinical features","Coronavirus disease 2019","Epidemic","Laboratory","Outcomes","SARS-CoV-2"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1663352133869633536,"score":358.69214}]}